JS203 in combination with gemcitabine and oxaliplatin

COMBINATION_PRODUCT2 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd.

Conditions

B-cell Non-Hodgkin's LymphomaDiffuse Large B-Cell Lymphoma

Phase 2

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Active, not recruitingNCT07081022

Shanghai Junshi Bioscience Co., Ltd.B-cell Non-Hodgkin's Lymphoma

Start: 2025-08-17End: 2027-04-06Target: 180Updated: 2026-09-04

Phase 3

A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not yet recruitingNCT07808827

Shanghai Junshi Bioscience Co., Ltd.Diffuse Large B-Cell Lymphoma

Start: 2026-09-24End: 2030-02-28Target: 282Updated: 2026-09-09